Clinical Trials Directory

Trials / Completed

CompletedNCT01652066

Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults

Effect of a Mixture of Probiotics ( Lactobacillus Gasseri PA16/8,Bifidobacterium Longum SP07/3, Bifidobacterium Bifidum MF 20/5) on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adult

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
430 (actual)
Sponsor
Merck Medication Familiale · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

the aim of the study is to get evidence for an enhancement of immune status in subjects after probiotics mixture consumption ( lactobacillus gasseri PA 16/8, Bifidobacterrium longum SP 07/3, Bifidobacterium bifidum MF 20/5) based on influenza vaccination model - compared to placebo.

Detailed description

probiotics are "live microorganisms which when administered in adequate amounts confer a health benefit on the host" . many health effects are associated with probiotics , but various degrees of evidence support the benefits associated to probiotics consumption . Impact on defences and the immune system has been shown with several strains and this may result in improved protection against some infections or improvment of vaccine efficacy . In its scientific requirments for health claims related to immune function, EFSA indicates that it is generally accepted that higher vaccination responses are beneficial.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTMixture of probioticseffect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
DIETARY_SUPPLEMENTMixture of probitiocseffect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense

Timeline

Start date
2011-05-01
Primary completion
2011-07-01
Completion
2011-12-01
First posted
2012-07-27
Last updated
2012-07-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01652066. Inclusion in this directory is not an endorsement.